KamadaKMDA
Recorded

Kamada 2026 Stifel Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration31 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Annabel SamimyAnalyst

All right, we're going to get started here. Good morning, everyone, and welcome to the Kamada session.

Annabel SamimyAnalyst

Special session. Special session. Kamada is a developer, a specialty plasma.

Annabel SamimyAnalyst

Oh my God, this is a mess. Specialty plasma company, diversified global specialty plasma company. Here with us to talk about it is Amir London, who is CEO of Kamada. Amir, welcome, and why don't I give you the floor and have you give an overview of Kamada and your unique place in this market?

Amir LondonCEO

Perfect. Thanks, Annabel, and thank you everyone for joining. Can you hear me well? Yes? Okay. Like Annabel said, Kamada is a specialty pharma, specialty plasma, global company, dual traded Tel Aviv and NASDAQ. We have six FDA-approved products. Over the last few years, we've grown significantly, double digit every year, top line and bottom line. We've expanded significantly our portfolio, and we have what we call the four pillars of growth. Organic growth coming from our six FDA-approved products in a very unique niche of specialty immunoglobulin, specialty plasma products. We have what we call the in-licensing of the distribution business, where we operate in Israel and the Middle East, and we license products from third parties, international companies, and we basically provide them with a turnkey solution in those territories.

Amir LondonCEO

Main focus over the last two years, and that will be our main growth engine in that area, are biosimilars. We have signed multiple agreements with different companies to represent them in the region, and we just launched two additional products in that space. Thirdly, we opened, over the last few years, plasma collection centers. We use a specialty plasma for our own need, but we also collect normal source plasma, and we recently signed a $50 million agreement to be selling that normal source plasma to an external client. Lastly, we are very active in terms of looking to grow also inorganically, through M&A and acquisition in the areas where we operate. We are searching for the right assets. We are looking for commercial assets. We would like to grow with very little risk in the way we are growing the business.

Amir LondonCEO

I like to say that Kamada currently has no binary events. Unlike many other biopharmaceutical companies, we are really focused on commercialization, distribution, and profitability. We had our earning call yesterday for the first nine months of the year, and I will leave it to you to ask me about it.

Annabel SamimyAnalyst

Okay. Well, tell us about your third quarter earnings call.

Amir LondonCEO

Yeah and- Yeah, so we had the.

Annabel SamimyAnalyst

How is the performance going?

Amir LondonCEO

Yeah. We had a very strong first nine months. This has been growing in all financial metrics, top line, bottom line, gross margins, cash. Last year, we basically started also paying dividend to our shareholders. That will be the third time this year we will be paying dividend. If you look at our EBITDA and cash generation, around $37 million of cash generated first nine months of the year, EBITDA of over $40 million, and dividend of around $32 million paid back to our shareholders. All of that with strong cash position, around $75 million. We do not need to go back to the market anytime soon in order to raise funds. We have sufficient resources also to execute the different execution or different acquisition that we would like to do. It is a very solid financial situation.

Annabel SamimyAnalyst

Okay. Maybe we can just step back a little bit for people who are not as familiar with the specialty plasma market. Can you talk about that market?

Annabel SamimyAnalyst

Yeah. It is relatively well protected.

Annabel SamimyAnalyst

It has got some high barriers to entry. Can you sort of describe that market and- Yeah.

Amir LondonCEO

In general, I think most of the plasma industry is around what's called IVIG and albumin. There are a few giants in that market, Grifols, CSL, Takeda. We have decided, basically almost from day one at Kamada, that we will be focusing on the specialty side of the plasma business. These are not commodity IVIG, but specialty immunoglobulins. The entry barrier is very high, and we are not finding new companies developing product in that space. The ability to collect a high titer, high potency plasma is complicated. It requires unique expertise to identify those, what we call the super donors, the one that have high titer, and then to bring them back into our centers and over and over again in order to donate plasma. The ability to quantify, and simplifying it a little bit, to quantify the plasma titer is also complicated.

Amir LondonCEO

You need to have special testing, what's called neutralization testing, to identify those specific donors. The fact that there is complexities and limitation around the plasma sourcing, you don't just pick up the phone, call a supplier somewhere, and order this raw material. This is a very unique, hard-to-make type of raw material, and we know how to do it. This is kind of the entry into that space. Adding to that is the only less than 10 companies worldwide that have an FDA-approved plasma products. That's all. So they have a high standard of manufacturing, regulatory compliance, quality GMP, and we know how to do it. We've been doing it for over 30 years, and over the last few years, we really found our kind of specialty niche in making those products.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day